Been digging through the market lately and honestly, finding solid growth stocks under $100 is harder than it used to be. But it's not impossible if you know where to look. The real advantage of sticking to this price range? You can diversify better and catch companies while they're still in early growth mode without dropping huge capital per share.

Let me walk you through three that caught my attention as genuinely interesting plays for the long term.

First up is CRISPR Therapeutics. This gene-editing biotech had a rough year, but something shifted when they got regulatory approval for Casgevy - a cell therapy they developed with Vertex. The FDA cleared it for sickle cell disease and beta-thalassemia, and here's the kicker: the price tag is over $2 million per treatment. That's massive for the company's financials going forward. CRISPR takes 40% of profits while Vertex gets the rest, but even that split should meaningfully improve their numbers as rollout happens. Trading around $51 a share, it's sitting well under $100 and honestly feels like one of the best stocks under $100 right now if you believe in the gene therapy narrative. The company's been disciplined about costs too, which is refreshing for a biotech with no revenue stream yet.

Then there's Celsius, the energy drink play. Stock got hammered when growth guidance came down, which actually created an opening. You can pick it up for under $30 now instead of flirting with $100 earlier in the year. The thing people overlook: PepsiCo is both a distributor and investor ($550M in 2022), which is serious validation. They're dealing with inventory adjustments right now, but that's temporary noise. There's still huge untapped market potential, and they've been profitable in 3 of the last 4 quarters. This is another solid entry for best stocks under $100 if you're thinking medium to long-term.

KB Home rounds out the list - homebuilder sitting just under $83 at the end of last year. Interest rates have been falling, which is tailwind for the entire sector. Their quarterly revenue hit $1.8 billion and grew over 10% year-over-year, with management noting strengthening demand. Trading at 11x trailing earnings, it's got that growth-and-value combo that's attractive. As rates keep normalizing, this could see real acceleration.

The pattern here is interesting: all three are best stocks under $100, all have near-term catalysts, and all are priced where you can actually build a position without committing a fortune. That's the real edge of staying in this price range - you get optionality and diversification together.